Takeda Oncology
Alan Copenhaver has extensive experience in the field of oncology and immunology, currently serving as Research Scientific Associate Director at Takeda Oncology since December 2017, with prior roles including Principal Scientist, Senior Scientist, Scientist II, and Scientist I. Before joining Takeda, Alan worked as a Postdoctoral Fellow at MedImmune from May 2015 to December 2017. Academic training includes a Doctor of Philosophy (Ph.D.) in Immunology from the University of Pennsylvania, where studies were conducted from 2010 to 2015, and a Bachelor of Science (BS) in Biology from Georgia State University, completed in 2009. Prior to graduate studies, Alan worked as a Research Technician at Georgia State University from January 2008 to August 2010.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.